CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...License Agreement • January 24th, 2025 • Aurion Biotech, Inc. • Biological products, (no disgnostic substances) • Washington
This Amended and Restated License Agreement (the “Agreement”), effective as of April 26, 2024 (the “Restatement Date”), is made by and between Dr. Shigeru Kinoshita (“Licensor”), and Aurion Biotech, Inc. (“Aurion”), a Delaware corporation, with offices at 117 E Louisa Street, Suite 561, Seattle, WA, United States, 98102. Each of Licensor and Aurion may be referred to herein as a “Party” or together as the “Parties.”
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...License Agreement • January 24th, 2025 • Aurion Biotech, Inc. • Biological products, (no disgnostic substances) • Washington
This Amended and Restated License Agreement (the “Agreement”), effective as of April 26, 2024 (the “Restatement Date”), is made by and between Kyoto Prefectural Public University Corporation DBA Kyoto Prefectural University of Medicine (“Licensor”), and Aurion Biotech. Inc. (“Aurion”). a Delaware corporation, with offices at 117 E Louisa Street, Suite 561, Seattle, WA, United States, 98102. Each of Licensor and Aurion may be referred to herein as a “Party” or together as the “Parties.”
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...License Agreement • December 10th, 2024 • Aurion Biotech, Inc. • Biological products, (no disgnostic substances) • Washington
This Amended and Restated License Agreement (the “Agreement”), effective as of April 26, 2024 (the “Restatement Date”), is made by and between Dr. Shigeru Kinoshita (“Licensor”), and Aurion Biotech, Inc. (“Aurion”), a Delaware corporation, with offices at 117 E Louisa Street, Suite 561, Seattle, WA, United States, 98102. Each of Licensor and Aurion may be referred to herein as a “Party” or together as the “Parties.”
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...License Agreement • December 10th, 2024 • Aurion Biotech, Inc. • Biological products, (no disgnostic substances) • Washington
This Amended and Restated License Agreement (the “Agreement”), effective as of April 26, 2024 (the “Restatement Date”), is made by and between Kyoto Prefectural Public University Corporation DBA Kyoto Prefectural University of Medicine (“Licensor”), and Aurion Biotech. Inc. (“Aurion”). a Delaware corporation, with offices at 117 E Louisa Street, Suite 561, Seattle, WA, United States, 98102. Each of Licensor and Aurion may be referred to herein as a “Party” or together as the “Parties.”